223 related articles for article (PubMed ID: 23345302)
1. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
[TBL] [Abstract][Full Text] [Related]
2. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
3. Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.
Saki M; Toulany M; Sihver W; Zenker M; Heldt JM; Mosch B; Pietzsch HJ; Baumann M; Steinbach J; Rodemann HP
Strahlenther Onkol; 2012 Sep; 188(9):823-32. PubMed ID: 22875052
[TBL] [Abstract][Full Text] [Related]
4. Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay.
Ingargiola M; Runge R; Heldt JM; Freudenberg R; Steinbach J; Cordes N; Baumann M; Kotzerke J; Brockhoff G; Kunz-Schughart LA
Int J Cancer; 2014 Aug; 135(4):968-80. PubMed ID: 24615356
[TBL] [Abstract][Full Text] [Related]
5. ²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells.
Pickhard A; Piontek G; Seidl C; Kopping S; Blechert B; Mißlbeck M; Brockhoff G; Bruchertseifer F; Morgenstern A; Essler M
Nucl Med Biol; 2014 Jan; 41(1):68-76. PubMed ID: 24210808
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro.
Eke I; Ingargiola M; Förster C; Kunz-Schughart LA; Baumann M; Runge R; Freudenberg R; Kotzerke J; Heldt JM; Pietzsch HJ; Steinbach J; Cordes N
Int J Radiat Biol; 2014 Aug; 90(8):678-86. PubMed ID: 24597752
[TBL] [Abstract][Full Text] [Related]
7. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential.
Koi L; Bergmann R; Brüchner K; Pietzsch J; Pietzsch HJ; Krause M; Steinbach J; Zips D; Baumann M
Radiother Oncol; 2014 Feb; 110(2):362-9. PubMed ID: 24440046
[TBL] [Abstract][Full Text] [Related]
9. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
10. (90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation.
Chakravarty R; Chakraborty S; Sarma HD; Nair KV; Rajeswari A; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):354-63. PubMed ID: 27264196
[TBL] [Abstract][Full Text] [Related]
11. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
12. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
Price EW; Edwards KJ; Carnazza KE; Carlin SD; Zeglis BM; Adam MJ; Orvig C; Lewis JS
Nucl Med Biol; 2016 Sep; 43(9):566-576. PubMed ID: 27419360
[TBL] [Abstract][Full Text] [Related]
13. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
16. The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining.
Kriegs M; Kasten-Pisula U; Rieckmann T; Holst K; Saker J; Dahm-Daphi J; Dikomey E
DNA Repair (Amst); 2010 Aug; 9(8):889-97. PubMed ID: 20615764
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation.
Ingargiola M; Dittfeld C; Runge R; Zenker M; Heldt JM; Steinbach J; Cordes N; Baumann M; Kotzerke J; Kunz-Schughart LA
Cytometry A; 2012 Oct; 81(10):865-73. PubMed ID: 22930585
[TBL] [Abstract][Full Text] [Related]
18. Modulation of endothelial cell network formation in vitro by molecular signaling of head and neck squamous cell carcinoma (HNSCC) exposed to cetuximab.
Jouan-Hureaux V; Boura C; Merlin JL; Faivre B
Microvasc Res; 2012 Mar; 83(2):131-7. PubMed ID: 21820450
[TBL] [Abstract][Full Text] [Related]
19. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
